Differences

This shows you the differences between two versions of the page.

--- worked_example4 [2016/04/12 08:50] – created dcrespo
+++ worked_example4 [2017/05/24 15:27] (current) – external edit 127.0.0.1
@@ Line 3: / Line 3: @@
 ===== Data and data source =====
-In this example we use gene expression data from a BRCA cancer sample (TCGA data, sample id {{:http://cancer.digitalslidearchive.net/index_mskcc.php?slide_name=TCGA-BH-A1FM-11B|TCGA.BH.A1FM}} - example data).
+In this example we use gene expression data from a BRCA cancer sample (TCGA data, sample id TCGA.BH.A1FM - example data).
+You can download the example file from {{:brca_example1_40_exp.txt|here}}.
 ===== Job description =====
@@ Line 24: / Line 26: @@
 Moreover, VEGF signaling pathway is not the only therapeutic related pathway, and PathAct shows similar In Silico effects in others pathways like HIF-1 signaling pathway (FLT1 circuit) or Focal adhesion pathway.
-{{ :sora4.png?900 |}}
+{{ :sora4.png?800 |}}
-{{ :sora5.png?900 |}}
+{{ :sora5.png?800 |}}
 Acting as multiple kinase inhibitor, sorafenib binds to others proteins like MAPK proteins, limiting the tumor growth and inducing apoptosis. In our model, we show how some pathways like RAP-1 or Sphingolipid signaling pathways provokes changes in cell cycle and growth and many others pathways alter transcription regulation, whose functional effect is tissue dependent.
-{{ :sora3.png?900 |}}
+{{ :sora6.png?800 |}}
-{{ :sora3.png?900 |}}
+{{ :sora7.png?800 |}}
+{{ :sora8.png?800 |}}